Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-AnalysisReportar como inadecuado

Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.


Adoptive immunotherapy AI has been applied in the treatment of non-small-cell lung cancer NSCLC patients, but the value of postoperative AI has been inconclusive largely as a result of the small number of patients included in each study. We performed a systematic review and meta-analysis to address this issue for patients with postoperative NSCLC.


Pubmed, Embase, Cochrane Library were searched for randomized controlled trials comparing adoptive immunotherapy with control therapies in postoperative NSCLC patients. The primary endpoint was overall survival. Hazard ratio HR was estimated and 95% confidence intervals CI were calculated using a fixed-effect model.


Compared with control therapies, analyses of 4 randomized controlled trials 472 patients showed a significant benefit of adoptive immunotherapy on survival hazard ratio HR 0.61, 95% CI 0.45–0.84, p = 0.002, and a 39% reduction in the relative risk of death no evidence of a difference between trials; p = 0.16, I² = 42%. In subgroup analyses by treatment cycles and treatment regimen, significant OS benefit was found in combination therapy of AI with chemotherapy, regardless of whether or not the treatment cycles were more than 10 cycles.


Adoptive immunotherapy has the potential to improve overall survival in postoperative NSCLC. The findings suggest this is a valid treatment option for these patients. Further randomized clinical trials are urgently needed.

Autor: Yuan Zeng , Wenli Ruan , Jiaxi He, Jianrong Zhang, Wenhua Liang, Yaoqi Chen, Qihua He, Jianxing He



Documentos relacionados